CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors.
“Dr. Nader brings an experienced executive’s knowledge of drug development and commercialization in the rare disease area to our board, and we look forward to his contributions to the company’s future,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
Dr. Nader has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharma since 2008. During his tenure, Dr. Nader transformed NPS Pharma into a leading global rare disease company. Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS Pharma in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior to that, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader currently serves as chairman of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry. He is also a Board member of the Biotechnology Industry Organization (BIO), the New Jersey Chamber of Commerce, Trevena, Inc. and Clementia Pharmaceuticals. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.